1. Immunology/Inflammation
  2. PD-1/PD-L1
  3. Nivolumab

Nivolumab  (Synonyms: BMS-936558; ONO-4538; MDX-1106)

Cat. No.: HY-P9903 Pureza: 99.63%
Technical Support

Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 946414-94-4

Tamaño Precio Stock Cantidad
Muestra gratis (100 μg)   Solicite ahora  
1 mg En stock
5 mg En stock
10 mg En stock
25 mg En stock
50 mg En stock
100 mg En stock
200 mg   Obtener un presupuesto  
500 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 22 publication(s) in Google Scholar

Top Publications Citing Use of Products

    Nivolumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2025 May 22;13(5):e011080.  [Abstract]

    Nivolumab (25 µg/mL). FCM analysis of effector cytokine expression, including IFN-γ, in CD8+T cells across different treatment groups. Histogram overlays depict cytokine expression levels, while bar graphs quantify the percentage of GZMB+, IFN-γ+, and perforin+CD8+ T cells.

    Nivolumab purchased from MedChemExpress. Usage Cited in: Adv Healthc Mater. 2025 Nov 28.

    Activated Jurkat cells were treated for 2 h with anti PD-1 monoclonal antibody (Nivolumab, 10 µg/mL) and then co-cultured with cancer-on-a-bead model for an additional 24 h in the continued presence of the antibody. T cells apoptosis/necrosis was analyzed with Annexin/PI staining by flow cytometry. The displayed dot plot represents one experiment, typical of three independent experiments conducted.

    Nivolumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Mar 22;15(1):2567.  [Abstract]

    Representative proliferation assay of co-cultures using patient-derived intratumor NKs and NCI-H23 cells. NK anti-tumor activity was assessed in the presence of BETi (1 µM OTX015) and/or the anti-PD-1 inhibitor Nivolumab (15 µg/mL; 24-72 h) (n = 3 co-cultures from a single patient).

    Nivolumab purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Aug 13:e177413.  [Abstract]

    Survival of low-grade glioma GEMM mice using Kaplan-Meier analysis. IgG: n = 20 mice (median survival [MS]: 110.5 days), anti–PD-1 (Nivolumab, 200 μg/mouse; i.p.; three times per week for 3 weeks): n = 20 mice (MS: 134.5 days), anti-TIM3: n = 21 mice (MS: 253 days). Statistics (log-rank test): control versus anti–PD-1 (Nivolumab), P = 0.64; control versus anti-TIM3, P < 0.01; anti-TIM3 versus anti–PD-1 (Nivolumab), P = 0.02.

    Nivolumab purchased from MedChemExpress. Usage Cited in: Mol Ther. 2022 Feb 2;30(2):621-631.  [Abstract]

    IFN-γ does not increase in the context of PD-L1−/P146R relative to PD-L1−/WT. Co-cultures of T cells and the GC cells with or without Nivolumab (1 ng/μL; 4 days). IFN-γ concentration was measured in the supernatant. The results showed that Nivolumab significantly enhanced IFN-γ secretion from T cells.
    • Actividad biológica

    • Pureza y Documentación

    • Referencias

    • Revisión del cliente

    Descripciòn

    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

    Isotype

    Human IgG4 kappa

    Recommend Isotype Controls
    Species Reactivity

    Human

    IC50 & Target

    PDCD1/PD-1/CD279

    In Vitro

    Nivolumab binds to CHO cells expressing PD-1 with an EC50 of 1.66 nM, but does not bind to the parental CHO cell line. Nivolumab binds to PD-1 on activated T cells with an EC50 of 0.64 nM. Nivolumab also inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with IC50 values of 2.52 and 2.59 nM, respectively. Nivolumab (1.5 ng/mL) can enhance T-cell reactivity in the presence of a T-cell receptor stimulus[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Nivolumab (10 and 50 mg/kg, i.v.) is well tolerated in cynomolgus monkeys. Serum chemistry changes are limited to a reversible 28% decrease in T3 at week 13 in females treated with 50 mg/kg. T4 and TSH levels are unchanged. In males treated with 50 mg/kg, there are no changes in T3, T4, or TSH levels. Nivolumab exposure increases in an approximately dose-proportional manner between 10 and 50 mg/kg, with no substantial sex differences noted[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ensayo clínico
    Gene ID

    5133  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay

    Conjugated

    Unconjugated

    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.

    Peso molecular

    143.62 kDa

    No. CAS
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Nivolumab]

    Envío

    Shipping with dry ice.

    Formulation

    Please refer to the lot-specific COA for specific buffer information.

    Almacenamiento

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Format
    • Human IgG4 kappa
    Biological Activity
    • Immobilized hu-PD-1-His can bind Nivolumab. The EC 50 for this effect is 6.195 ng/mL.
    • Flow cytometry analysis of PD-1 overexpression HEK293 cells labelling PD-1 with Nivolumab at 67nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells.
    Pureza y Documentación

    Purity: 99.63%

    Referencias
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Calculadora de molaridad

    • Calculadora de dilución

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Productos vistos recientemente:

    Consulta en línea

    Your information is safe with us. * Required Fields.

    Nombre del producto

     

    Requested Quantity *

    Nombre del solicitante *

     

    Saludo

    Direcciòn del E-mail *

     

    Número de teléfono *

    Department

     

    Nombre de la Organizaciòn *

    City

    Provincia

    Country or Region *

         

    Observaciones

    Consulta para venta a granel

    Inquiry Information

    Nombre del producto:
    Nivolumab
    Cat. No.:
    HY-P9903
    Cantidad:
    MCE Japan Authorized Agent: